Derek Archila
Stock Analyst at Wells Fargo
(3.46)
# 835
Out of 4,778 analysts
171
Total ratings
42.98%
Success rate
4.98%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics | Maintains: Equal-Weight | $11 → $10 | $5.66 | +76.68% | 5 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $60 → $26 | $8.13 | +219.80% | 5 | Mar 12, 2025 | |
| QTTB Q32 Bio | Maintains: Equal-Weight | $16 → $15 | $2.06 | +628.16% | 2 | Mar 12, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $723 → $741 | $604.86 | +22.51% | 11 | Feb 28, 2025 | |
| EXEL Exelixis | Downgrades: Equal-Weight | $36 | $37.71 | -4.53% | 3 | Feb 24, 2025 | |
| SEPN Septerna | Downgrades: Equal-Weight | $43 → $14 | $6.11 | +129.32% | 2 | Feb 18, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $40 → $51 | $18.41 | +177.02% | 3 | Feb 13, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $8 → $6 | $1.87 | +221.72% | 4 | Jan 30, 2025 | |
| ZYME Zymeworks | Maintains: Equal-Weight | $12 → $14 | $12.80 | +9.38% | 5 | Dec 19, 2024 | |
| KZR Kezar Life Sciences | Maintains: Equal-Weight | $11 → $9 | $5.61 | +60.43% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $70 | $62.10 | +12.72% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $18.19 | +147.39% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $12 → $6 | $1.66 | +262.54% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $2.17 | +453.00% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 | $14.80 | +82.43% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $2.52 | +415.87% | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $38 → $57 | $31.80 | +79.25% | 7 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $2.31 | +938.96% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $30 | $23.78 | +26.16% | 10 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $151 | $93.15 | +62.10% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.49 | +387.11% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $161.11 | +79.38% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $1.28 | +759.38% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $20.17 | +83.44% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.48 | +303.23% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $52.93 | -1.76% | 4 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $12.59 | +58.86% | 4 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $1.69 | +1,083.43% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.80 | +542.86% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.41 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $25.54 | +655.68% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $102.40 | -59.96% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $24 → $8 | $0.45 | +1,667.96% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $4.12 | +1,356.31% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.82 | +502.28% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $2.35 | +2,032.20% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $11.38 | +348.15% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $27.21 | +223.41% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $24.56 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $15.69 | - | 2 | Aug 3, 2017 |
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $5.66
Upside: +76.68%
Arvinas
Mar 12, 2025
Maintains: Overweight
Price Target: $60 → $26
Current: $8.13
Upside: +219.80%
Q32 Bio
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $2.06
Upside: +628.16%
argenx SE
Feb 28, 2025
Maintains: Overweight
Price Target: $723 → $741
Current: $604.86
Upside: +22.51%
Exelixis
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $37.71
Upside: -4.53%
Septerna
Feb 18, 2025
Downgrades: Equal-Weight
Price Target: $43 → $14
Current: $6.11
Upside: +129.32%
AnaptysBio
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $18.41
Upside: +177.02%
Zentalis Pharmaceuticals
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $1.87
Upside: +221.72%
Zymeworks
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $12.80
Upside: +9.38%
Kezar Life Sciences
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $5.61
Upside: +60.43%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $68 → $70
Current: $62.10
Upside: +12.72%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $18.19
Upside: +147.39%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $12 → $6
Current: $1.66
Upside: +262.54%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $2.17
Upside: +453.00%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $14.80
Upside: +82.43%
Dec 11, 2024
Maintains: Overweight
Price Target: $15 → $13
Current: $2.52
Upside: +415.87%
Dec 2, 2024
Upgrades: Overweight
Price Target: $38 → $57
Current: $31.80
Upside: +79.25%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $2.31
Upside: +938.96%
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $43 → $30
Current: $23.78
Upside: +26.16%
Oct 31, 2024
Maintains: Overweight
Price Target: $153 → $151
Current: $93.15
Upside: +62.10%
Oct 4, 2024
Initiates: Overweight
Price Target: $17
Current: $3.49
Upside: +387.11%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $161.11
Upside: +79.38%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $1.28
Upside: +759.38%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $20.17
Upside: +83.44%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.48
Upside: +303.23%
Apr 18, 2024
Maintains: Overweight
Price Target: $53 → $52
Current: $52.93
Upside: -1.76%
Feb 16, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $12.59
Upside: +58.86%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $1.69
Upside: +1,083.43%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $2.80
Upside: +542.86%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.41
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $25.54
Upside: +655.68%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $102.40
Upside: -59.96%
Mar 31, 2020
Maintains: Hold
Price Target: $24 → $8
Current: $0.45
Upside: +1,667.96%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $4.12
Upside: +1,356.31%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.82
Upside: +502.28%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $2.35
Upside: +2,032.20%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $11.38
Upside: +348.15%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $27.21
Upside: +223.41%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $24.56
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $15.69
Upside: -